|
|
|
|
Burzynski Research Institute Inc (BZYR) |
|
Price: $0.0413
$-0.01 
-25.719%
|
| Day's High:
| $0.0444
| Week Perf:
| 0.24 %
|
| Day's Low: |
$ 0.04 |
30 Day Perf: |
-51.35 % |
| Volume (M): |
18 |
52 Wk High: |
$ 0.16 |
| Volume (M$): |
$ 1 |
52 Wk Avg: |
$0.05 |
| Open: |
$0.04 |
52 Wk Low: |
$0.02 |
|
|
| Market Capitalization (Millions $) |
5 |
| Shares
Outstanding (Millions) |
131 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Burzynski Research Institute Inc
Company Address: 9432 Katy Freeway Houston 77055 TX
Company Phone Number: 335-5697 Stock Exchange / Ticker: NONE BZYR
| BZYR is expected to report next financial results on October 12, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Biomerica Inc
Biomerica Inc Faces Challenges as Revenue Falls and Losses Widen
Investors in Biomerica Inc are facing a challenging period, as the company reported a decline in revenue and widening losses for the March to May 31, 2023 time-frame. The company's financial performance has raised concerns among investors who are now questioning the future prospects of the company.
In terms of earnings per share, Biomerica Inc managed to improve, with a loss per share decreasing from $-0.14 to $-0.10 compared to the previous year. However, the company's revenue fell sharply by -79.099% from $5.30 million to $1.11 million, indicating a significant decline in sales for the comparable reporting season. Sequentially, revenue also decreased by -0.291%.
|
|
Oncocyte Corporation
In the wake of the most recent fiscal period, Oncocyte Corporation has unveiled concerning financial results, reporting a drastic decline in revenue and a significant increase in net loss per share. While the rest of the In Vitro and In Vivo Diagnostic Substances sector saw positive growth, Oncocyte Corporation struggled to maintain its foothold. This article seeks to shed light on the implications of the company's performance and its contrasting market sentiment.
Revenues and Net Loss Per Share:
Oncocyte Corporation's revenues plummeted by an alarming 57.562% to a mere $0.46 million in the most recent fiscal period. This decrease is significant, especially when compared to the corresponding financial report from the previous year. The net loss per share also stands out, swelling to $-1.07, further amplifying concerns among investors.
|
|
Neogen Corporation
Over the past five trading days, the stock of Neogen Corporation has experienced a decline of -4.7%. This brings the year-to-date performance of the stock to 47.44%. Additionally, the stock is currently 6.6% short off its 52-week high.
In its May 31, 2023 report, Neogen Corporation announced a net profit per share of $0.02 and revenue of $218.26 million. This reflects a sharp decline in income compared to the fourth quarter of 2022 when the company earned $0.14 EPS. However, during the same period, revenue rose by an impressive 72.256%. Neogen Corporation has clearly outperformed its peers in the In Vitro and In Vivo Diagnostic Substances sector, which only showed 12.35% revenue growth during this time.
|
|
Mymd Pharmaceuticals Inc
In recent developments within the In Vitro and In Vivo Diagnostic Substances industry, attention has been primarily focused on the performance of leading companies. However, there are some overlooked corporations that have released their financial numbers. One such corporation is MYMD, which announced an operating loss of $-5.781632 million for the second quarter of 2023.
Despite the disappointing financial performance, shareholders are eagerly waiting for MYMD's business strategy to evolve in the near future. They are placing less emphasis on the current operational results of the company, instead seeking a promising long-term plan. It is common for corporations to experience challenging periods as they strive to establish a robust business strategy. MYMD appears to have encountered one such period ending on June 30, 2023, as its deficit widened to $-4.168 million.
|
|
Aspira Women S Health Inc
Aspira Women's Health Inc, a leading company in the In Vitro and In Vivo Diagnostic Substances industry, recently announced strong financial results in their Jun 30 2023 report. Despite facing challenges such as diminishing returns, the company's revenue surged by an impressive 20.571% to $2.49 million compared to the same quarter the previous year.
In comparison to its industry peers, Aspira Women's Health Inc's growth in the second quarter of 2023 showed a favorable performance. While the industry as a whole experienced a 12.33% business elevation during the same period, Aspira Women's Health Inc surpassed this with a 20.571% increase in revenue. This indicates the company's ability to outperform and gain a competitive edge in the market.
|
| Per Share |
Current |
| Earnings (TTM) |
-0 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
0 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
0 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
